Cholestatic syndromes

Current Opinion in Gastroenterology

Volumn 18, Issue 3, 2002, Pages 314-329

  Trauner, Michael ^a   Boyer, James L ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CALCITONIN; CELECOXIB; CILASTATIN; CLONIDINE; COLCHICINE; CYCLOSPORIN; FLUCLOXACILLIN; FOSINOPRIL; GLIBENCLAMIDE; IMIPENEM; INFLIXIMAB; METFORMIN; NALTREXONE; NEVIRAPINE; PARACETAMOL; PAROXETINE; PIPERACILLIN; PROPAFENONE; PROPYLTHIOURACIL; RAPAMYCIN; RISPERIDONE; SILYMARIN; TERBINAFINE; TROGLITAZONE; UNINDEXED DRUG; URSODEOXYCHOLIC ACID; VITAMIN D; VITAMIN K GROUP; VOGLIBOSE;

BILE ACID METABOLISM; CHOLESTASIS; CHOLESTEROL STONE; CLINICAL FEATURE; DRUG MECHANISM; GENE MUTATION; GENE TRANSFER; HUMAN; LIVER DISEASE; LIVER TRANSPLANTATION; PATHOGENESIS; PRIMARY BILIARY CIRRHOSIS; REVIEW; WITHDRAWAL SYNDROME;

EID: 0036227670     PISSN: 02671379     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001574-200205000-00005     Document Type: Review

References (272)

1. Transport of bile acids in hepatic and non-hepatic tissues
2. The human ATP-binding cassette (ABC) transporter superfamily
3. Function and regulation of ATP-binding cassette transport proteins involved in hepatobiliary transport
4. Localization of organic anion transporting polypeptide 4 (Oatp4) in rat liver and comparison of its substrate specificity with Oatp1, Oatp2 and Oatp3
5. Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver
6. Hepatic uptake of cholecystokinin octapeptide by organic anion-transporting polypeptides oatp4 and oatp8 of rat and human liver
7. Characterization of the mouse bile salt export pump overexpressed in the baculovirus system
8. Tauroursodeoxycholic acid inserts the apical conjugate export pump, Mrp2, into canalicular membranes and stimulates organic anion secretion by protein kinase C-dependent mechanisms in cholestatic rat liver
9. Transporters on demand: Intrahepatic pools of canalicular ATP-binding cassette transporters in rat liver
10. The rat liver Na+/bile acid cotransporter: Importance of the cytoplasmic tail to function and plasma membrane targeting
11. Cell-specific basolateral membrane sorting of the human liver Na(+)-dependent bile acid cotransporter
12. Regulation of the dynamic localization of the rat Bsep gene-encoded bile salt export pump by anisoosmolarity
13. The water channel aquaporin-8 is mainly intracellular in rat hepatocytes, and its plasma membrane insertion is stimulated by cyclic AMP
14. Expression and localization of the multidrug resistance proteins mrp2 and mrp3 in human gallbladder epithelia
15. Bile acid transport and regulating functions in the human biliary epithelium
16. Cellular localization and up-regulation of multidrug resistance-associated protein 3 in hepatocytes and cholangiocytes during obstructive cholestasis in rat liver
17. Up-regulation of basolateral multidrug resistance protein 3 (Mrp3) in cholestatic rat liver
18. The expression levels of plasma membrane transporters in the cholestatic liver of patients undergoing biliary drainage and their association with the impairment of biliary secretory function
19. Sinusoidal efflux of taurocholate is enhanced in Mrp2-deficient rat liver
20. Disrupted bile acid homeostasis reveals an unexpected interaction among nuclear hormone receptors, transporters, and cytochrome P450
21. Protein kinase C-dependent distribution of the multidrug resistance protein 2 from the canalicular to the basolateral membrane in human HepG2 cells
22. Characterization of bile acid transport mediated by multidrug resistance associated protein 2 and bile salt export pump
23. Single amino acid substitution of rat MRP2 results in acquired transport activity for taurocholate
24. Bile acid feeding increased proliferative activity and apical bile acid transporter expression in both small and large rat cholangiocytes
25. Adaptive regulation of bile salt transporters in kidney and liver in obstructive cholestasis in the rat
26. Proinflammatory cytokines inhibit secretion in rat bile duct epithelium
27. Interleukin-5 inhibition of biliary cell chloride currents and bile flow
28. Upregulation of secretin receptors on cholangiocytes after bile duct ligation
29. Hepatobiliary transporter expression in percutaneous liver biopsies of patients with cholestatic liver diseases
30. Etiologic significance of defects in cholesterol, phospholipid, and bile acid metabolism in the liver of patients with intrahepatic calculi
31. Expression of hepatic transporters OATP-C and MRP2 in primary sclerosing cholangitis
32. Orphan nuclear receptors as eLiXiRs and FiXeRs of sterol metabolism
33. Orphan nuclear receptors: The exotics of xenobiotics
34. Human bile salt export pump promoter is transactivated by the famesoid X receptor/bile acid receptor
35. Nuclear receptor-mediated repression of human cholesterol 7alpha-hydroxylase gene transcription by bile acids
36. Down-regulation of cholesterol 7alpha-hydroxylase (CYPTA1) gene expression by bile acids in primary rat hepatocytes is mediated by the c-Jun N-terminal kinase pathway
37. The role of ap-1 in the transcriptional regulation of the rat apical sodium-dependent bile acid transporter
38. Suppression of bile acid synthesis, but not of hepatic cholesterol 7alpha-hydroxylase expression, by obstructive cholestasis in humans
39. Suppression of sterol 12alpha-hydroxylase transcription by the short heterodimer partner: Insights into the repression mechanism
40. The orphan nuclear receptor, shp, mediates bile acid-induced inhibition of the rat bile acid transporter, ntcp
41. Enhanced expression of the human multidrug resistance protein 3 by bile salt in human enterocytes: A transcriptional control of a plausible bile acid transporter
42. An essential role for nuclear receptors SXR/PXR in detoxification of cholestatic bile acids
43. The nuclear receptor PXR is a lithocholic acid sensor that protects against liver toxicity
44. Coordinate regulation of xenobiotic and bile acid homeostasis by pregnane X receptor
45. Differential effects of microsomal enzyme-inducing chemicals on the hepatic expression of rat organic anion transporters, OATP1 and OATP2
46. Effect of phenobarbital on the expression of bile salt and organic anion transporters of rat liver
47. Regulation of biliary drug efflux pump expression by hormones and xenobiotics
48. Chemical genomics: Functional analysis of orphan nuclear receptors in the regulation of bile acid metabolism
49. The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux
50. Farnesoid X-activated receptor induces apolipoprotein C-II transcription: A molecular mechanism linking plasma triglyceride levels to bile acids
51. Dehydroepiandrosterone sulfotransferase gene induction by bile acid activated farnesoid X receptor
52. Induction of Mdr1 b expression by tumor necrosis factor-alpha in rat liver cells is independent of p53 but requires NF-kappaB signaling
53. Lipopolysaccharide results in a marked decrease in hepatocyte nuclear factor 4alpha in rat liver
54. Hepatocyte nuclear factor-1 alpha is an essential regulator of bile acid and plasma cholesterol metabolism
55. Hepatocyte nuclear factor 4alpha (nuclear receptor 2A1) is essential for maintenance of hepatic gene expression and lipid homeostasis
56. Transcriptional regulation of the human sterol 12alpha-hydroxylase gene (CYP8B1): Roles of hepatocyte nuclear factor 4alpha in mediating bile acid repression
57. Characterization of the human OATP-C (SLC21A6) gene promoter and regulation of liver-specific OATP genes by hepatocyte nuclear factor 1 alpha
58. Alterations in vesicle transport and cell polarity in rat hepatocytes subjected to mechanical or chemical cholestasis
59. Phospholipid alterations in hepatocyte membranes and transporter protein changes in cholestatic rat model
60. Dilated bile canaliculi and attenuated decrease of nerve-dependent bile secretion in connexin32-deficient mouse liver
61. Ursodeoxycholic acid: Mechanisms of action and clinical use in hepatobiliary disorders
62. Use of ursodeoxycholic acid in liver diseases
63. Effect of sodium tauroursodeoxycholate on phalloidin-induced cholestasis in rats
64. Effect of tauroursodeoxycholate and S-adenosyl-L-methionine on 17β-estradiol glucuronide-induced cholestasis
65. Endotoxin increases paracellular permeability of isolated rat hepatocyte couplets
66. Effects of ursodeoxycholic and cholic acid feeding on hepatocellular transporter expression in mouse liver
67. Bile-salt hydrophobicity is a key factor regulating rat liver plasma-membrane communication: Relation to bilayer structure, fluidity and transporter expression and function
68. Tauroursodesoxycholate-induced choleresis involves p38(MAPK) activation and translocation of the bile salt export pump in rats
69. Stimulation of ATP secretion in the liver by therapeutic bile acids
70. Metabolism and effects on cholestasis of isoursodeoxycholic and ursodeoxycholic acids in bile duct ligated rats
71. Functional modulation of the glucocorticoid receptor and suppression of NF-kappaB-dependent transcription by ursodeoxycholic acid
72. Tauroursodeoxycholic acid protects hepatocytes from ethanol-fed rats against tumor necrosis factor-induced cell death by replenishing mitochondrial glutathione
73. Amyloid beta-peptide disrupts mitochondrial membrane lipid and protein structure: Protective role of tauroursodeoxycholate
74. A bile acid protects against motor and cognitive deficits and reduces striatal degeneration in the 3-nitropropionic acid model of Huntington's disease
75. Bilirubin-induced apoptosis in cultured rat neural cells is aggravated by chenodeoxycholic acid but prevented by ursodeoxycholic acid
76. Ursodeoxycholic acid and in vitro vasoactivity of hydrophobic bile acids
77. Beneficial effects of silymarin on estrogen-induced cholestasis in the rat: A study in vivo and in isolated hepatocyte couplets
78. The effect of trimetazidine on intrahepatic cholestasis caused by carmustine in rats
79. Characterization of the protective effects of melatonin and related indoles against alpha-naphthylisothiocyanate-induced liver injury in rats
80. Melatonin protects against renal oxidative stress after obstructive jaundice in rats
81. Melatonin versus vitamin E as protective treatment against oxidative stress after extra-hepatic bile duct ligation in rats
82. Presence of melatonin in the human hepatobiliary-gastrointestinal tract
83. Proliferating bile duct epithelial cells are a major source of connective tissue growth factor in rat biliary fibrosis
84. Modulation of collagen XVIII/endostatin expression in lobular and biliary rat liver fibrogenesis
85. Antifibrotic effect of silymarin in rat secondary biliary fibrosis is mediated by downregulation of procollagen alpha1 (I) and TIMP-1
86. Effect of angiotensin II type 1 receptor blockade on experimental hepatic fibrogenesis
87. Regression of liver fibrosis after biliary drainage in patients with chronic pancreatitis and stenosis of the common bile duct
88. Genes and cholestasis
89. ABC of diseases of liver, pancreas, and biliary system: Other causes of parenchymal liver disease
90. Genetic disorders and molecular mechanisms in cholestatic liver disease: A clinical approach
91. FIC1 disease: A spectrum of intrahepatic cholestatic disorders
92. Familial intrahepatic cholestasis 1: Studies of localization and function
93. FIG1, the protein affected in two forms of hereditary cholestasis, is localized in the cholangiocyte and the canalicular membrane of the hepatocyte
94. FIC1: Another bile salt carrier within the enterohepatic circulation?
95. BSEP: Function and role in progressive familial intrahepatic cholestasis
96. Targeted inactivation of sister of P-glycoprotein gene (spgp) in mice results in non-progressive but persistent intrahepatic cholestasis
97. Mice and men: Are they bile-ologically different?
98. Bile secretion in mice and men
99. Bile salt export pump is highly conserved during vertebrate evolution and its expression is inhibited by PFIC type II mutations
100. Role of multidrug resistance 3 deficiency in pediatric and adult liver disease: One gene for three diseases
101. The wide spectrum of multidrug resistance 3 deficiency: From neonatal cholestasis to cirrhosis of adulthood
102. Progressive familial intrahepatic cholestasis with high gamma-glutamyltranspeptidase levels in Taiwanese infants: Role of MDR3 gene defect?
103. Mdr3 gene defect in adults with symptomatic intrahepatic and gallbladder cholesterol cholelithiasis
104. Chromosomal organization of candidate genes involved in cholesterol gallstone formation: A murine gallstone map
105. Two genes that map to the STSL locus cause sitosterolemia: Genomic structure and spectrum of mutations involving sterolin-1 and sterolin-2, encoded by ABCG5 and ABCG8, respectively
106. Identification of a gene, ABCG5, important in the regulation of dietary cholesterol absorption
107. Alagille syndrome and the JAGGED1 gene
108. Notch receptor expression in adult human liver: A possible role in bile duct formation and hepatic neovascularization
109. Jagged1 mutations in Alagille syndrome
110. Parental mosaicism of JAG1 mutations in families with Alagille syndrome
111. Mutation analysis of Jagged1 (JAG1) in Alagille syndrome patients
112. Fifteen novel mutations in the JAGGED1 gene of patients with Alagille syndrome
113. Defective intracellular transport and processing of JAG1 missense mutations in Alagille syndrome
114. The DSL domain in mutant JAG 1 ligand is essential for the severity of the liver defect in Alagille syndrome
115. Outcome of liver disease in children with Alagille syndrome: A study of 163 patients
116. Cholangiocyte biology and cystic fibrosis liver disease
117. Ileal mucosal bile acid absorption is increased in Cftr knockout mice
118. Taurocholic acid-induced secretion in normal and cystic fibrosis mouse ileum
119. Ursodeoxycholic acid action on the transport function of the small intestine in normal and cystic fibrosis mice
120. Intestinal bile acid transport: Biology, physiology, and pathophysiology
121. Absense of dysfunctional ileal sodium-bile acid cotransporter gene mutations in patients with adult-onset idiopathic bile acid malabsorption
122. Bile acid malabsorption in microscopic colitis and in previously unexplained functional chronic diarrhea
123. An association between genetic polymorphisms in the ileal sodium-dependent bile acid transporter gene and the risk of colorectal adenomas
124. Diminished gene expression of ileal apical sodium bile acid transporter explains impaired absorption of bile acid in patients with hypertriglyceridemia
125. Analysis of the ileal bile acid transporter gene, SLC10A2, in subjects with familial hypertriglyceridemia
126. The natural history of primary biliary cirrhosis: Of genes and cooperation
127. Primary biliary cirrhosis: From induction to destruction
128. Genetic and familial considerations of primary biliary cirrhosis
129. HLA and interleukin 1 gene polymorphisms in primary biliary cirrhosis: Associations with disease progression and disease susceptibility
130. Apolipoprotein E polymorphism, a marker of disease severity in primary biliary cirrhosis?
131. Single nucleotide polymorphisms of the mannose-binding lectin are associated with susceptibility to primary biliary cirrhosis
132. The geographical distribution of primary biliary cirrhosis in a well-defined cohort
133. Primary biliary cirrhosis among atomic bomb survivors in Nagasaki, Japan
134. Autoantibodies of sera from patients with primary biliary cirrhosis recognize the alpha subunit of the decarboxylase component of human branched-chain 2-oxo acid dehydrogenase complex
135. Molecular mimicry and primary biliary cirrhosis: Premises not promises
136. Heterogeneous response of antimitochondrial autoantibodies and bile duct apical staining monoclonal antibodies to pyruvate dehydrogenase complex E2: The molecule versus the mimic
137. Immunogenetic analysis reveals that epitope shifting occurs during B-cell affinity maturation in primary biliary cirrhosis
138. Immunoglobulin gene usage and immunohistochemical characteristics of human monoclonal antibodies to the mitochondrial autoantigens of primary biliary cirrhosis induced in the XenoMouse
139. Spontaneous occurrence of chronic non-suppurative destructive cholangitis and antimitochondrial autoantibodies in MRL/Ipr mice: Possible animal model for primary biliary cirrhosis
140. Peripheral blood T-cell responses to pyruvate dehydrogenase complex in primary biliary cirrhosis: Role of antigen-presenting dendritic cells
141. The immune response to alkaline phosphatase and other immunogens in patients with primary biliary cirrhosis
142. Primary biliary cirrhosis and primary sclerosing cholangitis are of infectious origin!
143. Molecular identification of bacterial 165 ribosomal RNA gene in liver tissue of primary biliary cirrhosis: Is Propionibacterium acnes involved in granuloma formation?
144. Scavenger cells with gram-positive bacterial lipoteichoic acid infiltrate around the damaged interlobular bile ducts of primary biliary cirrhosis
145. Alterations in tight junctions differ between primary biliary cirrhosis and primary sclerosing cholangitis
146. Antibodies to Clp protease in primary biliary cirrhosis: Possible role of a mimicking T-cell epitope
147. Evidence of an increased nitric oxide production in primary biliary cirrhosis
148. Monocyte chemotactic protein-1, -2, and -3 are distinctively expressed in portal tracts and granulomata in primary biliary cirrhosis: Implications for pathogenesis
149. Bile acids regulate RANTES gene expression through its cognate NF-kappaB binding sites
150. Bile acids induce eosinophil degranulation by two different mechanisms
151. Identification of novel molecules and pathogenic pathways in primary biliary cirrhosis: cDNA array analysis of intrahepatic differential gene expression
152. Aberrant expression of cytokeratin 7 as a histological marker of progression in primary biliary cirrhosis
153. Bile duct cell apoptosis is a rare event in primary biliary cirrhosis
154. Cholangiocytic apoptosis in chronic ductopenic rejection
155. Viewing apoptosis through a 'TUNEL'
156. Apoptotic pathways in primary biliary cirrhosis and autoimmune hepatitis
157. Increased expression of WAF1 in intrahepatic bile ducts in primary biliary cirrhosis relates to apoptosis
158. Novel bile acid derivatives induce apoptosis via a p53-independent pathway in human breast carcinoma cells
159. The bile acid glycochenodeoxycholate induces trail-receptor 2/DR5 expression and apoptosis
160. The bile acid-activated phosphatidylinositol 3-kinase pathway inhibits Fas apoptosis upstream of bid in rodent hepatocytes
161. Phosphoinositide 3-kinase, but not mitogen-activated protein kinase, pathway is involved in hepatocyte growth factor-mediated protection against bile acid-induced apoptosis in cultured rat hepatocytes
162. Bid antisense attenuates bile acid-induced apoptosis and cholestatic liver injury
163. Bile acid-induced rat hepatocyte apoptosis is inhibited by antioxidants and blockers of the mitochondrial permeability transition
164. Bcl-2-dependent oxidation of pyruvate dehydrogenase-E2, a primary biliary cirrhosis autoantigen, during apoptosis
165. Autoantibodies in liver disease
166. Changes in titers of antimitochondrial and antinuclear antibodies during the course of primary biliary cirrhosis
167. Detection of antimitochondrial auto-antibodies in immunofluorescent AMA-negative patients with primary biliary cirrhosis using recombinant autoantigens
168. High sensitivity of a novel ELISA for anti-M2 in primary biliary cirrhosis
169. A comparative study of antibody expressions in primary biliary cirrhosis and autoimmune cholangitis using phage display
170. Similar T-cell oligoclonality in antimitochondrial antibody-positive and -negative primary biliary cirrhosis
171. The follow-up of asymptomatic persons with antibodies to pyruvate dehydrogenase in adult population samples
172. Autoantibodies against nuclear pore complexes are associated with more active and severe liver disease in primary biliary cirrhosis
173. Jaundice in non-cirrhotic primary biliary cirrhosis: The premature ductopenic variant
174. Autoimmune overlap syndromes
175. Autoimmune hepatitis and its variant syndromes
176. Are primary biliary cirrhosis and autoimmune cholangitis reflective of the pendulum of a clock and therefore represent a 'phase' of the same disease?
177. Development of autoimmune hepatitis in the setting of long-standing primary biliary cirrhosis
178. Consecutive occurrence of primary biliary cirrhosis and autoimmune hepatitis: A case report and review of the literature
179. Autoimmune hepatitis with incidental histologic features of bile duct injury
180. Antipyrine clearance and metabolite formation in primary biliary cirrhosis
181. Caffeine metabolism in a group of 67 patients with primary biliary cirrhosis
182. Primary biliary cirrhosis: MR imaging findings and description of MR imaging periportal halo sign
183. Primary biliary cirrhosis: Clinical, pathologic, and helical CT findings in 53 patients
184. Hepatocellular carcinoma in primary biliary cirrhosis: Similar incidence to that in hepatitis C virus-related cirrhosis
185. Ursodeoxycholic acid for primary biliary cirrhosis
186. Ursodeoxycholic acid for primary biliary cirrhosis: Lesson for the future?
187. Lichenoid eruptions due to ursodeoxycholic acid administration
188. Incomplete response to ursodeoxycholic acid in primary biliary cirrhosis: Is a double dosage worthwhile?
189. Isoursodeoxycholic acid: Metabolism and therapeutic effects in primary biliary cirrhosis
190. Ten-year combination treatment with colchicine and ursodeoxycholic acid for primary biliary cirrhosis: A double-blind, placebo-controlled trial on symptomatic patients
191. Differences in the efficacy of ursodeoxycholic acid and bile acid metabolism between viral liver diseases and primary biliary cirrhosis
192. Hyperlipidemia in chronic cholestatic liver disease
193. Cholesterol metabolism in primary biliary cirrhosis during simvastatin and UDCA administration
194. Effect of bezafibrate in primary biliary cirrhosis: A pilot study
195. Pilot study of bright-light therapy reflected toward the eyes for the pruritus of chronic liver disease
196. Delayed opioid withdrawal-like reaction in primary biliary cirrhosis following naloxone therapy
197. Clonidine attenuates naloxone-induced opioid-withdrawal syndrome in cholestatic mice
198. Liver transplantation for intractable pruritus is contra-indicated before an adequate trial of opiate antagonist therapy
199. Grip strength and subjective fatigue in patients with primary biliary cirrhosis
200. Decreased orexigenic response to neuropeptide Y in rats with obstructive cholestasis
201. Bone disease in primary biliary cirrhosis: Independent indicators and rate of progression
202. Osteoporosis in primary biliary cirrhosis revisited
203. Fat-soluble vitamin levels in patients with primary biliary cirrhosis
204. Randomized pilot trial of vitamin K2 for bone loss in patients with primary biliary cirrhosis
205. A controlled trial of calcitonin therapy for the prevention of post-liver transplantation atraumatic fractures in patients with primary biliary cirrhosis and primary sclerosing cholangitis
206. Transdermal oestrogen therapy protects postmenopausal liver transplant women from osteoporosis: A 2-year follow-up study
207. A model to predict survival in patients with end-stage liver disease
208. Living-related liver transplantation for primary biliary cirrhosis
209. Disease recurrence after living liver transplantation for primary biliary cirrhosis: A clinical and histological follow-up study
210. Cyclosporin A reduces canalicular membrane fluidity and regulates transporter function in rats
211. Cholestasis and regulation of genes related to drug metabolism and biliary transport in rat liver following treatment with cyclosporine A and sirolimus (Rapamycin)
212. Effect of bile acids on biliary excretion of cyclosporin A in the rat
213. Cholestatic potential of troglitazone as a possible factor contributing to troglitazone-induced hepatotoxicity: In vivo and in vitro interaction at the canalicular bile salt export pump (Bsep) in the rat
214. Troglitazone-induced intrahepatic cholestasis by an interference with the hepatobiliary export of bile acids in male and female rats: Correlation with the gender difference in troglitazone sulfate formation and the inhibition of the canalicular bile salt export pump (Bsep) by troglitazone and troglitazone sulfate
215. The effect of troglitazone biliary excretion on metabolite distribution and cholestasis in transporter-deficient rats
216. The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: A potential mechanism for hepatic adverse reactions
217. Acute hepatocellular and cholestatic injury in a patient taking celecoxib
218. Drug points: Cholestatic hepatitis in association with celecoxib
219. Celecoxib-induced cholestatic hepatitis
220. Severe cholestatic hepatitis from troglitazone in a patient with nonalcoholic steatohepatitis and diabetes mellitus
221. Hepatic necrosis with cholestasis induced by long-term voglibose administration
222. Infliximab-associated reversible cholestatic liver disease
223. Fosinopril-induced prolonged cholestatic jaundice and pruritus: First case report
224. Jaundice and hepatocellular damage associated with nevirapine therapy
225. The incidence and clinical characteristics of symptomatic propylthiouracil-induced hepatic injury in patients with hyperthyroidism: A single-center retrospective study
226. Acute cholestatic hepatitis caused by a probable allergic reaction to paracetamol in an adolescent
227. Severe hepatotoxicity with jaundice associated with paroxetine
228. Cholestatic jaundice associated with the use of metformin
229. Terbinafine-induced hepatic dysfunction
230. Acute cholestatic hepatitis caused by propafenone: Report of a case and review of the literature
231. Risperidone-induced cholestatic hepatitis
232. Cholangiopathy after short-term administration of piperacillin and imipenem/cilastatin
233. Azathioprine-induced destructive cholangitis
234. Indirect cytotoxicity of flucloxacillin toward human biliary epithelium via metabolite formation in hepatocytes
235. Benzylpenicillin-induced prolonged cholestasis
236. Stevens-Johnson syndrome and cholestatic hepatitis
237. Ursodeoxycholic acid and prevention of tacrine-induced hepatotoxicity: A pilot study
238. The causes of obvious jaundice in south west Wales: Perceptions versus reality
239. Sepsis presenting with severe jaundice
240. Sclerosing cholangitis and liver cirrhosis after extrabiliary infections: Report on three cases
241. Cholestasis as a presenting feature of acute Epstein-Barr virus infection
242. Infectious mononucleosis presenting with severe cholestatic liver disease in the elderly
243. Cytomegalovirus infection and proinflammatory cytokine activation modulate the surface immune determinant expression and immunogenicity of cultured murine extrahepatic bile duct epithelial cells
244. Acute hepatitis E virus infection presenting as a prolonged cholestatic jaundice
245. Cholestatic presentation of chronic hepatitis C: A clinical and histological study with a review of the literature
246. Detection of hepatitis C virus in the bile and bile duct epithelial cells of hepatitis C virus-infected patients
247. Increased levels of gammaGT suggest the presence of bile duct lesions in patients with chronic hepatitis C: Absence of influence of HCV genotype, HCV-RNA serum levels, and HGV infection on this histological damage
248. Cholestatic diseases of liver transplantation
249. Successful treatment with adefovir dipivoxil in a patient with fibrosing cholestatic hepatitis and lamivudine resistant hepatitis B virus
250. Cholestatic syndrome with bile duct damage and loss in renal transplant recipients with HCV infection
251. Fibrosing cholestatic hepatitis-like syndrome in hepatitis B virus-negative and hepatitis C virus-negative renal transplant recipients
252. Risk of obstetric cholestasis in sisters of index patients
253. Maternal susceptibility locus for obstetric cholestasis maps to chromosome region 2p13 in Finnish patients
254. Insertion-deletion polymorphism in the gene for angiotensin-converting enzyme is associated with obstetric cholestasis but not with preeclampsia
255. Ursodeoxycholic acid administration in patients with cholestasis of pregnancy: Effects on primary bile acids in babies and mothers
256. Ursodeoxycholic acid for the treatment of intrahepatic cholestasis of pregnancy
257. Interventions for treating cholestasis in pregnancy
258. The bile acid taurocholate impairs rat cardiomyocyte function: A proposed mechanism for intra-uterine fetal death in obstetric cholestasis
259. Altered cellular calcium regulatory systems in a rat model of cirrhotic cardiomyopathy
260. The changing pattern of diagnosis of infantile cholestasis
261. Etiopathogenesis of biliary atresia
262. Evaluation of the triangular cord sign in the diagnosis of biliary atresia
263. Technical innovation for noninvasive and early diagnosis of biliary atresia: The ultrasonographic "triangular cord" sign
264. Hepatic technetium-99m-mebrofenin iminodiacetate scans and serum gamma-glutamyl transpeptidase levels interpreted in series to differentiate between extrahepatic biliary atresia and neonatal hepatitis
265. Beneficial effect of a traditional herbal medicine (inchin-ko-to) in postoperative biliary atresia patients
266. Parenteral nutrition-associated cholestasis
267. Manganese intake and cholestatic jaundice in neonates receiving parenteral nutrition: A randomized controlled study
268. Long-term prospective study of the effect of ursodeoxycholic acid on cystic fibrosis-related liver disease
269. Mucopolysaccharidosis type VII (Sly syndrome) presenting as neonatal cholestasis with hepatosplenomegaly
270. Cholestasis in juvenile dermatomyositis: Report of three cases
271. Idiopathic adulthood ductopenia: Long-term follow-up after liver transplantation
272. Association of HLA-DR genes with mild idiopathic adulthood biliary ductopenia